Literature DB >> 20187069

The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.

Lori E Weinberg1, Gustavo Rodriguez, Jean A Hurteau.   

Abstract

The current management of advanced ovarian cancer consists of aggressive primary cytoreductive surgery (PCS) followed by combination platinum based chemotherapy. Recent studies have suggested that platinum-based chemotherapy may be of benefit in patients with advanced ovarian cancer prior to cytoreductive surgery (neoadjuvant chemotherapy, NACT). The concept of NACT has not been completely validated in the treatment of ovarian cancer. This review will discuss the role of NACT in patients with advanced epithelial ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20187069     DOI： 10.1002/jso.21482

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  10 in total

1.  Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-04-15       Impact factor: 5.482

2.  Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-09-26       Impact factor: 5.482

3.  Bim protein degradation contributes to cisplatin resistance.

Authors:  Juan Wang; Jun-Ying Zhou; Gen Sheng Wu
Journal:  J Biol Chem       Date:  2011-05-11       Impact factor: 5.157

4.  The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Authors:  Jiangxue Qu; Yuehan Li; Shujie Liao; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?

Authors:  Joseph Menczer; Irena Usviatzov; Erez Ben-Shem; Abraham Golan; Tally Levy
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

6.  Stonin 2 Overexpression is Correlated with Unfavorable Prognosis and Tumor Invasion in Epithelial Ovarian Cancer.

Authors:  Xiaoying Sun; Weijing Zhang; Han Li; Chunhao Niu; Yulan Ou; Libing Song; Yanna Zhang
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

7.  Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy

Authors:  Natalia V Yunusova; Alisa B Villert; Liudmila V Spirina; Alena E Frolova; Larisa A Kolomiets; Irina V Kondakova
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

8.  Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.

Authors:  Kira Philipsen Prahm; Claus Høgdall; Mona Aarenstrup Karlsen; Ib Jarle Christensen; Guy Wayne Novotny; Steen Knudsen; Anker Hansen; Peter Buhl Jensen; Thomas Jensen; Mansoor Raza Mirza; Anne Weng Ekmann-Gade; Lotte Nedergaard; Estrid Høgdall
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

9.  microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells.

Authors:  Hao Li; Haiyuan Xu; Huiling Shen; Hao Li
Journal:  Oncol Lett       Date:  2013-10-29       Impact factor: 2.967

Review 10.  Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer.

Authors:  Yang Shao; Hui Li; Ran Du; Jiao Meng; Gong Yang
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.